BIOMARKERS OF AMINO ACID COMPOSITION TREATMENT RESPONSE IN LONG COVID

This disclosure provides biomarkers for assessing response to a therapy for post-acute sequelae of COVID-19 (PASC). In some embodiments, the biomarker comprises NfL, IL-26, Activin, GPX3, GSR, FGF21, or VCAM1. La présente divulgation concerne des biomarqueurs permettant d'évaluer une réponse à...

Full description

Saved in:
Bibliographic Details
Main Authors PRADINES, Joel, LEAF, Irina, LAVERY, Karen, AZER, Karim
Format Patent
LanguageEnglish
French
Published 08.02.2024
Subjects
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
TESTING
Online AccessGet full text

Cover

More Information
Summary:This disclosure provides biomarkers for assessing response to a therapy for post-acute sequelae of COVID-19 (PASC). In some embodiments, the biomarker comprises NfL, IL-26, Activin, GPX3, GSR, FGF21, or VCAM1. La présente divulgation concerne des biomarqueurs permettant d'évaluer une réponse à une thérapie pour des séquelles post-aiguës du SARS-CoV-2 (PASC). Dans certains modes de réalisation, le biomarqueur comprend NfL, IL-26, activine, GPX3, GSR, FGF21, ou VCAM1.
Bibliography:Application Number: WO2023US71437